tricyclo[5,2,1,02,6 ]decane-8-yl-amine | 669-51-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: tricyclo[5,2,1,02,6 ]decane-8-yl-amine
• 英文别名: 9-Amino-tetrahydro-dicyclopentadien；8-Amino-tricyclo[5.2.1.0^2,6]decan；Tricyclo[5.2.1.0,2,6]decan-8-amine；tricyclo[5.2.1.02,6]decan-8-amine
• CAS: 669-51-2
• 化学式: C₁₀H₁₇N
• mdl: MFCD09263281
• 分子量: 151.252
• InChiKey: CRGOACNDJXEJHP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  tricyclo[5,2,1,02,6 ]decane-8-yl-amine 、 3-(benzyloxy)-4-chlorobenzaldehyde 生成 N-[(4-chloro-3-phenylmethoxyphenyl)methyl]tricyclo[5.2.1.02,6]decan-8-amine
  参考文献：
  名称：

  AT335420

  摘要：

  公开号：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 镍 氢气 作用下， 生成 tricyclo[5,2,1,02,6 ]decane-8-yl-amine
  参考文献：
  名称：

  Benzenesulfonyl ureas

  摘要：

  公开号：

  US03812185A1

文献信息

• Benzylamine derivatives and process for preparing them
  申请人：Hoechst Aktiengesellschaft

  公开号：US04024274A1

  公开（公告）日：1977-05-17

  N-Cycloalkyl-benzylamine derivatives of the formula ##STR1## in which R.sup.1 represents hydrogen or lower alkyl of 1 to 4 carbon atoms, R.sup.2 represents a cycloalkyl radical of a total of 7 to 12 carbon atoms which may be alkyl-substituted and may contain hydrocarbon bridges of 1 to 3 carbon atoms, R.sup.3 represents hydrogen, alkoxy of 1 to 4 carbon atoms, R.sup.4 represents hydrogen or alkoxy of 1 to 4 carbon atoms or halogen, and R.sup.5 represents alkoxy of 1 to 4 carbon atoms, methylene dioxy, ethylene dioxy, benzyloxy or halogen, and the physiologically tolerated salts thereof are disclosed as having diuretic and saluretic activity.

  公开了公式##STR1##中的N-环烷基-苄胺衍生物，其中R.sup.1代表氢或1到4个碳原子的较低烷基，R.sup.2代表总共7到12个碳原子的环烷基基团，可能是烷基取代的，可能含有1到3个碳原子的碳氢桥，R.sup.3代表氢，1到4个碳原子的烷氧基，R.sup.4代表氢或1到4个碳原子的烷氧基或卤素，R.sup.5代表1到4个碳原子的烷氧基，亚甲二氧基，乙二氧基，苄氧基或卤素，以及其生理耐受的盐，具有利尿和排钠活性。
• Substituted norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics, and a medicament comprising them
  申请人：——

  公开号：US20010023257A1

  公开（公告）日：2001-09-20

  The application discloses substituted norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics and a medicament comprising them Substituted norbornylamino derivatives having exo-configured nitrogen and an endo-fused five-membered ring of the formula I, or having exo-configured nitrogen and an exo-fused five-membered ring of the formula I a 1 in which R1, R2, R3, R4, R5, A, B, S1, and S2 are as defined in the claims, are highly suitable for use as antihypertensive agents, for reducing or preventing ischemically induced damage, for use as medicaments for surgical interventions for the treatment of ischemias of the nervous system, of stroke and cerebral edema, of shock, of impaired respiratory drive, for the treatment of snoring, as laxatives, as agents against ectoparasites, for the prevention of the formation of biliary calculus, as antiatherosclerotics, as agents against late diabetic complications, carcinomatous disorders, fibrotic disorders, endothelial dysfunction, and organ hypertrophies and hyperplasias. They are inhibitors of the cellular sodium/proton antiporter. They have an influence on serum lipoproteins and can therefore be used for the prophylaxis and regression of atherosclerotic changes.

  该申请公开了取代的诺博烯基氨基衍生物，其制备方法，它们作为药物或诊断工具的用途以及包含它们的药物。具有式I中的外向构型氮和内向融合的五元环，或具有式I a1中的外向构型氮和外向融合的五元环的取代诺博烯基氨基衍生物，其中R1，R2，R3，R4，R5，A，B，S1和S2如权利要求所定义，非常适用于用作降压剂，用于减少或预防缺血性损伤，用作治疗神经系统缺血，中风和脑水肿，休克，呼吸驱动力受损的手术干预药物，用于治疗打鼾，作为泻药，对抗外寄生虫药物，预防胆石形成，作为抗动脉粥样硬化药物，对抗晚期糖尿病并发症，癌症疾病，纤维病性疾病，内皮功能障碍以及器官肥大和增生。它们是细胞钠/质子抗转运体的抑制剂。它们对血清脂蛋白有影响，因此可以用于动脉粥样硬化变化的预防和回归。
• Substituted heterocyclo-norbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostics, and medicaments comprising them
  申请人：——

  公开号：US20020173500A1

  公开（公告）日：2002-11-21

  Substituted heterocyclo-norbornylaminoderivatives having: a) an exo-configuration nitrogen and an endo-fused five-membered ring or six-membered ring of the formula (I) or b) an exo-configuration nitrogen and an exo-fused five-membered ring or six-membered ring of the formula (Ia), 1 wherein R n , Het, A, B and T have the meanings given in the claims. These compounds have a variety of uses. They can be used as antihypertensives, for the reduction or prevention of is chemically induced damage, as pharmaceuticals for surgical interventions, for the treatment of ischemia of the nervous system, including stroke and cerebral edema, for the treatment of ischemia due to shock and disturbed respiratory drive, for the treatment of snoring, as a laxative, as an agent against ectoparasites, for the prevention of gallstone formation, as an antiatherosclerotic, as an agent against diabetic late complications, cancers, fibrotic disorders, endothelial dysfunction, organ hypertrophy, and organ hyperplasia. The compounds of the invention are inhibitors of the cellular sodium-proton antiporter. Additonally, the compounds of the invention influence the serum lipoproteins and can therefore be used for the prophylaxis and the regression of atherosclerotic changes.

  具有以下结构的取代杂环-去氢萘基氨基衍生物：a）具有外向构型的氮和内向融合的五元环或六元环的式（I）或b）具有外向构型的氮和外向融合的五元环或六元环的式（Ia），其中Rn，Het，A，B和T具有权利要求中给出的含义。这些化合物具有各种用途。它们可以用作降压药，用于减少或预防化学诱导的损伤，作为手术干预的药物，用于治疗神经系统缺血，包括中风和脑水肿，用于治疗休克和呼吸驱动障碍引起的缺血，用于治疗打鼾，作为泻药，用作抗外寄生虫剂，用于预防胆结石形成，作为抗动脉粥样硬化药物，用作抗糖尿病晚期并发症、癌症、纤维化疾病、内皮功能障碍、器官肥大和器官增生的药物。本发明化合物是细胞钠-质子抗运输蛋白的抑制剂。此外，本发明化合物影响血清脂蛋白，因此可用于动脉粥样硬化变化的预防和回归。
• INHIBITION OF INFLUENZA M2 PROTON CHANNEL
  申请人：DeGrado William F.

  公开号：US20110288111A1

  公开（公告）日：2011-11-24

  Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being capable of interaction with the M2 protein.

  提供了一些化合物，这些化合物能够通过与M2跨膜蛋白相互作用来调节甲型流感病毒的活性。同时还提供了一种治疗甲型流感受影响的疾病状态或感染的方法，包括给予含有已被鉴定为能够与M2蛋白相互作用的一个或多个化合物的组合物。
• Procédé d'obtention d'acides pyrazole-3-carboxyliques
  申请人：SANOFI

  公开号：EP0885889A2

  公开（公告）日：1998-12-23

  L'invention concerne un procédé pour l'obtention d'acides pyrazole-3-carboxyliques de formule :    ou qui consiste à traiter le composé de formule : pour une base forte dans un solvant ; à faire réagir l'anion obtenu avec le composé de formule : puis à hydrolyser le composé obtenu en milieu alcalin.

  本发明涉及一种获得式......或......的吡唑-3-羧酸的工艺： 或 式的化合物的工艺，包括在溶剂中用强碱处理式： 在溶剂中用强碱处理 使得到的阴离子与式......化合物反应 然后在碱性介质中水解得到的化合物。